3-Deoxysappanchalcone
Based on 2 publication(s) in Google Scholar
3-Deoxysappanchalcone is a natural chalcone compound isolated from the heartwood of Caesalpinia sappan L. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection.
For research use only. We do not sell to patients.
- Purity : 99.77%
- CAS No.: 112408-67-0
- Formula: C16H14O4
- Molecular Weight:270.28
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) 3-Deoxysappanchalcone
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | IC50 |
41.8 μM
Compound: 6
|
Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining
Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining
|
[PMID: 19757853] |
| A549 | IC50 |
32.6 μM
Compound: 11
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 21800859] |
| A549 | IC50 |
62.1 μM
Compound: 29
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| A549 | IC50 |
66.5 μM
Compound: 26
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| B16-BL6 | IC50 |
49.9 μM
Compound: 26
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| B16-BL6 | IC50 |
56.3 μM
Compound: 29
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| Ca9-22 | IC50 |
57.56 μM
Compound: 11
|
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
|
[PMID: 21800859] |
| HeLa | IC50 |
33.3 μM
Compound: 26
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| HeLa | IC50 |
67.9 μM
Compound: 29
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| Hep 3B2 | IC50 |
17.89 μM
Compound: 11
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 21800859] |
| HepG2 | IC50 |
7.37 μM
Compound: 11
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 21800859] |
| HT-1080 | IC50 |
26.7 μM
Compound: 26
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 19689125] |
| HT-1080 | IC50 |
51.2 μM
Compound: 29
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| Lewis lung carcinoma cell line | IC50 |
69.1 μM
Compound: 29
|
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| MCF7 | IC50 |
51.41 μM
Compound: 11
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 21800859] |
| MDA-MB-231 | IC50 |
44.44 μM
Compound: 11
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 21800859] |
| RAW264.7 | IC50 |
8.1 μM
Compound: 13
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
|
[PMID: 23127886] |
In Vitro
3-Deoxysappanchalcone (12 h) directly binds to EGFR and MET proteins in HCC827GR Gefitinib (HY-50895)-resistant human lung adenocarcinoma cells[1].
3-Deoxysappanchalcone (3-12 μM; 1 h) inhibits purified EGFR kinase activity with dose-dependent efficacy[1].
3-Deoxysappanchalcone (3-12 μM; 24-48 h) reduces HCC827GR Gefitinib-resistant human lung adenocarcinoma cell viability in a dose- and time-dependent manne[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces apoptotic cell death in HCC827GR Gefitinib-resistant human lung adenocarcinoma cells in a dose-dependent manner[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces G2/M cell cycle arrest and increases apoptotic sub-G1 cell population in HCC827GR Gefitinib-resistant human lung adenocarcinoma cells[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) inhibits phosphorylation of EGFR, MET, AKT, and ERK in HCC827GR Gefitinib-resistant human lung adenocarcinoma cells, reducing p-EGFR to 0.31-fold and p-MET to 0.24-fold of control at 12 μM after 48 h[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) increases intracellular ROS levels and induces ER stress in HCC827GR Gefitinib-resistant human lung adenocarcinoma cells[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces mitochondrial depolarization and intrinsic mitochondrial apoptosis in HCC827GR Gefitinib-resistant human lung adenocarcinoma cells, and modulating Bcl-2 family proteins and cytochrome C translocation[1].
3-Deoxysappanchalcone (5-50 μM; 48 h) exhibits no cytotoxicity in HUVECs at concentrations up to 50 μM following 48 h of incubation[4].
3-Deoxysappanchalcone (2-20 μM; 18 h) dose-dependently suppresses TNF-α-stimulated PAI-1 secretion in HUVECs at concentrations of 2, 3, 5, 10, and 20 μM over 18 h, mitigating the TNF-α-induced increase in the PAI-1/t-PA ratio without significantly affecting t-PA secretion[4].
3-Deoxysappanchalcone inhibits influenza virus A/PR/8/34 (H1N1) NA with an IC50 of 14.6 μg/mL[5].
3-Deoxysappanchalcone inhibits influenza virus A/Guangdong/243/72 (H3N2) NA with an IC50 of 17.4 μg/mL[5].
3-Deoxysappanchalcone inhibits influenza virus B/Jiangsu/10/2003 NA with an IC50 of 18.6 μg/mL[5].
3-Deoxysappanchalcone inhibits influenza virus A/Guangdong/243/72 (H3N2)-induced cytopathic effects in MDCK cells with an IC50 of 1.06 μg/mL, a CC50 of 17.25 μg/mL, and a selective index of 16.27[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCC827GR gefitinib-resistant human lung adenocarcinoma cells
-
Concentration:3 μM; 6 μM; 9 μM; 12 μM
-
Incubation Time:24 h; 48 h
-
Result:Reduced HCC827GR cell viability in a dose- and time-dependent manner.
-
Cell Line:HCC827GR gefitinib-resistant human lung adenocarcinoma cells
-
Concentration:6 μM; 9 μM; 12 μM
-
Incubation Time:48 h
-
Result:Induced apoptotic cell death in a dose-dependent manner.
-
Cell Line:HCC827GR gefitinib-resistant human lung adenocarcinoma cells
-
Concentration:6 μM; 9 μM; 12 μM
-
Incubation Time:48 h
-
Result:Increased the sub-G1 (apoptotic) cell population and induced G2/M cell cycle arrest.
-
Cell Line:HCC827GR gefitinib-resistant human lung adenocarcinoma cells
-
Concentration:6 μM; 9 μM; 12 μM
-
Incubation Time:48 h
-
Result:Reduced phosphorylation of EGFR (Tyr1068) to 0.88-, 0.76-, and 0.31-fold of control at 6, 9, and 12 μM, respectively, without altering total EGFR protein levels.
Reduced phosphorylation of MET (Tyr1234/1235) to 0.94-, 0.27-, and 0.24-fold of control at 6, 9, and 12 μM, respectively, without altering total MET protein levels.
Reduced phosphorylation of downstream AKT (Ser473) to 0.72-, 0.39-, and 0.32-fold of control, and phosphorylation of ERK (Thr202/Tyr204) to 0.88-, 0.85-, and 0.68-fold of control at 6, 9, and 12 μM, respectively, without altering total AKT or ERK protein levels.
-
Cell Line:Human umbilical vein endothelial cells (HUVECs)
-
Concentration:2 μM; 3 μM; 5 μM; 10 μM; 20 μM
-
Incubation Time:18 h
-
Result:Markedly suppressed TNF-α-stimulated PAI-1 release in a concentration-dependent fashion, with significant inhibition observed from 5 μM onward.
Did not significantly affect t-PA secretion from HUVECs.
Mitigated the TNF-α-induced increase in the PAI-1/t-PA ratio.
In Vivo
3-Deoxysappanchalcone (0.02-0.4 mg/kg; i.v.) significantly prolongs tail bleeding time in male C57BL/6 mice at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg, with the highest tested dose (0.4 mg/kg) extending bleeding time to 82.3 s[4].
3-Deoxysappanchalcone (0.02-0.4 mg/kg; i.v.) significantly prolongs ex vivo aPTT and PT in male C57BL/6 mice at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg, with the highest tested dose (0.4 mg/kg) increasing aPTT to 47.9 ± 0.8 s and PT to 29.4 ± 1.2 s[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 20-22 g, LPS-induced systemic inflammation)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose (1 hour prior to LPS challenge)
-
Result:Achieved 100% survival rate over 6 days.
-
Animal Model:C57BL/6 (male, 6-7 weeks old, 27 g)[4]
-
Dosage:0.02 mg/kg; 0.04 mg/kg; 0.06 mg/kg; 0.1 mg/kg; 0.2 mg/kg; 0.4 mg/kg
-
Administration:i.v.
-
Result:Prolonged tail bleeding time to 48.1 s at 0.1 mg/kg, 63.1 s at 0.2 mg/kg, and 82.3 s at 0.4 mg/kg.
Prolonged ex vivo aPTT to 35.4 s and PT to 23.8 s at 0.1 mg/kg, aPTT to 38.5 s and PT to 28.7 s at 0.2 mg/kg, and aPTT to 47.9 s and PT to 29.4 s at 0.4 mg/kg.
Chemical Information
-
CAS No. 112408-67-0
-
Appearance Solid
-
Molecular Weight 270.28
-
Formula C16H14O4
-
Color Light yellow to yellow
-
SMILES
O=C(/C=C/C1=CC=C(C=C1)O)C2=CC=C(C=C2OC)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
PLoS One
3-Deoxysappanchalcone attenuates LPS-induced neuroinflammation in microglia cell culture and ameliorates cognitive impairment in traumatic brain injury. [Abstract]2025 May 30;20(5):e0323259. PMID: 40445975 -
Oxid Med Cell Longev
Attenuation of the Severity of Acute Respiratory Distress Syndrome by Pomiferin through Blocking Inflammation and Oxidative Stress in an AKT/Foxo1 Pathway-Dependent Manner. [Abstract]2022 Nov 26:2022:5236908. PMID: 36471865
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (184.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee JY, et al. 3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases. Biomol Ther (Seoul). 2023;31(4):446-455. [Content Brief]
[2]. Kim JH, et al. The anti-inflammatory effect of 3-deoxysappanchalcone is mediated by inducing heme oxygenase-1 via activating the AKT/mTOR pathway in murine macrophages. Int Immunopharmacol. 2014;22(2):420-426. [Content Brief]
[3]. Kwak AW, et al. The 3-deoxysappanchalcone induces ROS-mediated apoptosis and cell cycle arrest via JNK/p38 MAPKs signaling pathway in human esophageal cancer cells. Phytomedicine. 2021;86:153564. [Content Brief]
[4]. Han G, et al. Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity. Molecules. 2025;30(12):2580. Published 2025 Jun 13. [Content Brief]
[5]. Liu AL, et al. In vitro anti-influenza viral activities of constituents from Caesalpinia sappan. Planta Med. 2009;75(4):337-339. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | 92.4967 mL |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | 18.4993 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL | 9.2497 mL | |
| 15 mM | 0.2467 mL | 1.2333 mL | 2.4666 mL | 6.1664 mL | |
| 20 mM | 0.1850 mL | 0.9250 mL | 1.8499 mL | 4.6248 mL | |
| 25 mM | 0.1480 mL | 0.7400 mL | 1.4799 mL | 3.6999 mL | |
| 30 mM | 0.1233 mL | 0.6166 mL | 1.2333 mL | 3.0832 mL | |
| 40 mM | 0.0925 mL | 0.4625 mL | 0.9250 mL | 2.3124 mL | |
| 50 mM | 0.0740 mL | 0.3700 mL | 0.7400 mL | 1.8499 mL | |
| 60 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5416 mL | |
| 80 mM | 0.0462 mL | 0.2312 mL | 0.4625 mL | 1.1562 mL | |
| 100 mM | 0.0370 mL | 0.1850 mL | 0.3700 mL | 0.9250 mL |